Navigation Links
Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
Date:5/13/2013

NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed a key patent application in the Company's portfolio.  The patent application "Alpha Emitting Constructs and Uses Thereof" is licensed by Actinium Pharmaceuticals from Memorial Sloan Kettering Cancer Center (MSKCC). 

The application covers treatment of metastatic solid cancers by targeting either cancer cells directly or blood vessels that provide for their growth with appropriate carriers of alpha emitting isotopes actinium 225 and bismuth 213.  This technology allows Actinium Pharmaceuticals to expand use of its platform beyond blood borne and bone marrow located cancers, thus potentially offering broad categories of severely ill patients an efficacious therapy with a safety profile that could allow treatment of such patients.  The patent is expected to issue in the next few months. Actinium Pharmaceuticals retains an exclusive license to use, develop, and commercialize this patent.

Dragan Cicic , MD, CMO of Actinium Pharmaceuticals, said: "This decision is an important step towards our goal of expanding the use of our technology to address the vast unmet medical need area of metastatic cancers in older patients.  We have the potential to not only improve efficacy of cancer treatment but also enable it in many patients too sick to withstand the rigors of currently available therapies."

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or Contact:

Segio Traversa , CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr. , 203-258-0159
Email: dsdobson@optonline.com 
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
2. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
3. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
4. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
5. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
6. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
7. Actinium Pharmaceuticals Announces New Round of Financing
8. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
9. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
10. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
11. Actinium Pharmaceuticals Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):